Skip to main content

Hereditary Angioedema Types I and II

A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema
NCT01912456 | PHASE 3 | INTERVENTIONAL

The aim of this study is to assess the efficacy of C1-esterase inhibitor in preventing hereditary angioedema attacks when it is administered under the skin of subjects with hereditary angioedema. The safety of C1-esterase inhibitor will also be assessed. Each subject will enter a run-in period of up to 8-weeks. Subjects who complete the run-in period and who are eligible will then enter the treatment phase which comprises two sequential treatment periods. In the treatment phase, subjects will be randomized to one of four arms consisting of treatment with low- or higher-volume C1-esterase inhibitor in one treatment period and treatment with low- or higher-volume placebo in the other treatment period. The study will measure the number of hereditary angioedema attacks that subjects experience while receiving each treatment.

Trial Information
39 Sites
90 Participants
Recruiting
12 Years to 50 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Study Site
Birmingham,Alabama,United States,35209
Study Site
Scottsdale,Arizona,United States,85251
Study Site
Bell Gardens,California,United States,90201
Study Site
La Jolla,California,United States,92093
Study Site
Orange,California,United States,92868
Study Site
Walnut Creek,California,United States,94598
Study Site
Colorado Springs,Colorado,United States,80907
Study Site
Chevy Chase,Maryland,United States,20815
Study Site
Boston,Massachusetts,United States,02114
Study Site
Cincinnati,Ohio,United States,45267
Study Site
Columbus,Ohio,United States,43235
Study Site
Toledo,Ohio,United States,43617
Study Site
Tulsa,Oklahoma,United States,74136
Study Site
Lake Oswego,Oregon,United States,97035
Study Site
Hershey,Pennsylvania,United States,17033
Study Site
Dallas,Texas,United States,75231
Study Site
Richmond,Virginia,United States,23298
Study Site
Virginia Beach,Virginia,United States,23452
Study Site
Spokane,Washington,United States,99204
Study Site
Campbelltown,New South Wales,Australia,2560
Study Site
Hamilton,Ontario,Canada,L8N3Z5
Study Site
Ottawa,Ontario,Canada,K1Y4G2
Study Site
Toronto,Ontario,Canada,M4V1R2
Study Site
Quebec,Canada,G1V4M6
Study Site
Hradec Kralove,Czechia,50005
Study Site
Plzen,Czechia,30460
Study Site
Budapest,Hungary,1125
Study Site
Tel Aviv,Israel,64239
Study Site
Tel Hashomer,Israel,52621
Study Site
Catania,Italy,95123
Study Site
Palermo,Italy,90146
Study Site
Cluj Napoca,Romania,400139
Study Site
Mures,Romania,540103
Study Site
Barcelona,Spain,08035
Study Site
Madrid,Spain,28007
Study Site
Madrid,Spain,28046
Study Site
Valencia,Spain,46026
Study Site
Brighton,United Kingdom,BN25BE
Study Site
London,United Kingdom,E12ES

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov